The Effect of Creatine Supplementation Associated With Resistance Training on Sarcopenia Parameters and Muscle Density in Prostate Cancer Patients After Androgen Deprivation Therapy
Condition: Prostate Cancer, Sarcopenia
Study Type: Interventional
Clinical Trials Identifier NCT 8-digits: NCT07463092
Sponsor: University of Sao Paulo
Eligibility:
- Age: minimum 40 Years maximum N/A
- Gender: Male
Inclusion Criteria:
- Men aged ≥ 40 years;
- Patients with histologically or cytologically confirmed localized prostate cancer;
- Patients who have undergone surgical castration or pharmacological castration with gonadotropin-releasing hormone (GnRH/LHRH) agonists or antagonists for at least six months prior to the start of the intervention;
- Patients receiving continuous or intermittent androgen deprivation therapy;
- Patients with an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2;
- Not engaged in resistance training in the three months prior to the intervention;
- Not using creatine supplementation in the three months prior to the intervention;
- Willing to participate in a 12-week intervention consisting of resistance training performed three times per week and daily supplementation with creatine monohydrate or maltodextrin.
Exclusion Criteria:
- Patients with insulin-dependent diabetes mellitus;
- Patients with dialysis-dependent renal failure;
- Patients with severe chronic liver disease;
- Estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m²;
- Any hormonal treatment outside that established by the medical team;
- Patients planning to undergo chemotherapy within the next six months.
View trial on ClinicalTrials.gov